Sangamo BioSciences Inc. (NASDAQ:SGMO)’s share price traded down 5.1% during trading on Wednesday . The stock traded as low as $4.64 and last traded at $4.67, with a volume of 604,364 shares changing hands. The stock had previously closed at $4.92.

A number of brokerages have recently weighed in on SGMO. Cowen and Company reiterated a “buy” rating on shares of Sangamo BioSciences in a research note on Wednesday. Jefferies Group reiterated a “buy” rating on shares of Sangamo BioSciences in a research note on Friday, August 5th. Janney Montgomery Scott downgraded shares of Sangamo BioSciences from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $15.00 to $8.00 in a research report on Thursday, August 4th. Zacks Investment Research downgraded shares of Sangamo BioSciences from a “hold” rating to a “sell” rating in a research report on Tuesday, July 5th. Finally, Wedbush reissued an “outperform” rating and set a $30.00 price objective on shares of Sangamo BioSciences in a research report on Friday, May 6th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the stock. Sangamo BioSciences currently has an average rating of “Buy” and a consensus price target of $15.58.

The stock’s market capitalization is $322.72 million. The firm’s 50-day moving average price is $5.79 and its 200-day moving average price is $6.04.

Sangamo BioSciences (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, August 3rd. The biopharmaceutical company reported ($0.38) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.24) by $0.14. The company had revenue of $3.70 million for the quarter, compared to analyst estimates of $5.38 million. During the same quarter in the previous year, the business posted ($0.17) earnings per share. The firm’s revenue for the quarter was down 56.0% on a year-over-year basis. On average, equities research analysts forecast that Sangamo BioSciences Inc. will post ($1.11) EPS for the current year.

An institutional investor recently raised its position in Sangamo BioSciences stock. Royce & Associates LLC raised its stake in shares of Sangamo BioSciences Inc. (NASDAQ:SGMO) by 47.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 312,100 shares of the biopharmaceutical company’s stock after buying an additional 100,000 shares during the period. Royce & Associates LLC owned 0.45% of Sangamo BioSciences worth $2,849,000 at the end of the most recent quarter.

Sangamo Biosciences Inc is a clinical-stage biopharmaceutical company. The Company is focused on research, development and commercialization of engineered deoxyribonucleic acid (DNA)-binding proteins for therapeutic genome editing and gene regulation. It is engaged in developing zinc finger DNA-binding proteins (ZFP) therapeutics.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.